DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Impact of COVID-19 Pandemic on Patients with Serious Mental Illness (SMI) and Nonpsychiatric Control Subjects in Clinical Trials

by Maria Fe Garcia-Rada, MPS, and Robert E. Litman, MD Ms. Fe Garcia-Rada and Dr. Litman are with CenExel CBH Health in Gaithersburg, Maryland. Dr. Litman is additionally with Georgetown

Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward

by William P. Horan, PhD; Gary Sachs, MD; Dawn I. Velligan, PhD; Michael Davis, MD, PhD; Richard S.E. Keefe, PhD; Ni A. Khin, MD; Florence Butlen-Ducuing, MD, PhD; and Philip

Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group

by Gahan J. Pandina, PhD; Joan Busner, PhD; Lucas Kempf, MD; Joan Fallon, BS, DC; Larry D. Alphs, MD, PhD; Maria T. Acosta, MD; Anna-Karin Berger, PhD; Simon Day, PhD;